Matches in SemOpenAlex for { <https://semopenalex.org/work/W2992113823> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2992113823 endingPage "10" @default.
- W2992113823 startingPage "6" @default.
- W2992113823 abstract "AIM To study effects of leflunomide on inflammatory and destructive processes in patients with early rheumatoid arthritis (RA). MATERIAL AND METHODS The trial included 33 patients (27 females and 6 males) with a significant diagnosis of RA (A CR criteria) aged 19 to 60 years and duration of the disease from 6 months to 3 years (15.97 +/- 9.70 months). The activity of the inflammatory process and treatment efficacy were assessed by severity of the articular syndrome, duration of morning stiffness (DMS), pain and the disease activity (VAS), device examination, the disease activity by DAS28 indices, etc. The articular syndrome was assessed by the number of painful joints (NPJ), number of swollen joints (NSJ), etc. The functional status of the patient was evaluated by Keitel test, HAQ and hand grip. Calculations were made of erosive arthritis progression rate (EAPR) and joint fissure narrowing progression rate (FNPR). All the patients received leflunomide (100 mg/day for 3 days, then 20 mg/day). A 12-month course was finished by 14 patients, 4 patients were withdrawn because of side effects, the rest--by social causes. RESULTS To the end of the trial leflunomide reduced NPJ by 84%, NSJ--by 95%, DMS--by 88%, articular pain by VAS--by 66%, the disease activity by VAS--by 70%. A positive trend in DAS28 criterium was observed (a significant suppression of RA activity after 1 month of therapy by 18%, after 4 months--by 39%, after 6 months--by 43%, by the end of the treatment--by 48%). For the initial 6 months EAPR was 0.50 +/- 0.67, for the following 6 months it lowered to 0.37 +/- 1.00, while FNPR decreased to 1.14 +/- 1.26 vs. 1.31 +/- 2 58 for initial 6 months. A positive change of the level of type 3 matrix metalloproteinase (a 20% and 16% by month 4 and to the end of the trial, respectively) was registered. CONCLUSION A positive effect of leflunomide on RA inflammatory activity and progression rate of joint destruction was confirmed." @default.
- W2992113823 created "2019-12-13" @default.
- W2992113823 creator A5015971984 @default.
- W2992113823 creator A5034015295 @default.
- W2992113823 creator A5040266006 @default.
- W2992113823 creator A5047705636 @default.
- W2992113823 creator A5078472154 @default.
- W2992113823 date "2006-01-01" @default.
- W2992113823 modified "2023-09-24" @default.
- W2992113823 title "An antidestructive effect of leflunomide in early rheumatoid arthritis" @default.
- W2992113823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16881355" @default.
- W2992113823 hasPublicationYear "2006" @default.
- W2992113823 type Work @default.
- W2992113823 sameAs 2992113823 @default.
- W2992113823 citedByCount "0" @default.
- W2992113823 crossrefType "journal-article" @default.
- W2992113823 hasAuthorship W2992113823A5015971984 @default.
- W2992113823 hasAuthorship W2992113823A5034015295 @default.
- W2992113823 hasAuthorship W2992113823A5040266006 @default.
- W2992113823 hasAuthorship W2992113823A5047705636 @default.
- W2992113823 hasAuthorship W2992113823A5078472154 @default.
- W2992113823 hasConcept C126322002 @default.
- W2992113823 hasConcept C141071460 @default.
- W2992113823 hasConcept C2775905006 @default.
- W2992113823 hasConcept C2776260265 @default.
- W2992113823 hasConcept C2777077863 @default.
- W2992113823 hasConcept C2777433710 @default.
- W2992113823 hasConcept C2777575956 @default.
- W2992113823 hasConcept C2909196033 @default.
- W2992113823 hasConcept C71924100 @default.
- W2992113823 hasConcept C90924648 @default.
- W2992113823 hasConceptScore W2992113823C126322002 @default.
- W2992113823 hasConceptScore W2992113823C141071460 @default.
- W2992113823 hasConceptScore W2992113823C2775905006 @default.
- W2992113823 hasConceptScore W2992113823C2776260265 @default.
- W2992113823 hasConceptScore W2992113823C2777077863 @default.
- W2992113823 hasConceptScore W2992113823C2777433710 @default.
- W2992113823 hasConceptScore W2992113823C2777575956 @default.
- W2992113823 hasConceptScore W2992113823C2909196033 @default.
- W2992113823 hasConceptScore W2992113823C71924100 @default.
- W2992113823 hasConceptScore W2992113823C90924648 @default.
- W2992113823 hasIssue "6" @default.
- W2992113823 hasLocation W29921138231 @default.
- W2992113823 hasLocation W29921138232 @default.
- W2992113823 hasOpenAccess W2992113823 @default.
- W2992113823 hasPrimaryLocation W29921138231 @default.
- W2992113823 hasRelatedWork W2041314287 @default.
- W2992113823 hasRelatedWork W2072925417 @default.
- W2992113823 hasRelatedWork W2304225013 @default.
- W2992113823 hasRelatedWork W2322293030 @default.
- W2992113823 hasRelatedWork W2357647844 @default.
- W2992113823 hasRelatedWork W2378404833 @default.
- W2992113823 hasRelatedWork W2383497351 @default.
- W2992113823 hasRelatedWork W2385212395 @default.
- W2992113823 hasRelatedWork W2419643449 @default.
- W2992113823 hasRelatedWork W2436497122 @default.
- W2992113823 hasRelatedWork W2474982294 @default.
- W2992113823 hasRelatedWork W2553028587 @default.
- W2992113823 hasRelatedWork W3029783847 @default.
- W2992113823 hasRelatedWork W3030245665 @default.
- W2992113823 hasRelatedWork W3030249434 @default.
- W2992113823 hasRelatedWork W3081255671 @default.
- W2992113823 hasRelatedWork W3095341738 @default.
- W2992113823 hasRelatedWork W3123276334 @default.
- W2992113823 hasRelatedWork W3210406711 @default.
- W2992113823 hasRelatedWork W81728145 @default.
- W2992113823 hasVolume "78" @default.
- W2992113823 isParatext "false" @default.
- W2992113823 isRetracted "false" @default.
- W2992113823 magId "2992113823" @default.
- W2992113823 workType "article" @default.